Stable injectable compositions of glp-2 peptide
US-2024415933-A1 · Dec 19, 2024 · US
Methods and compositions for treating hypoglycemic disorders
US9821031B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9821031-B2 |
| Application number | US-52227408-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 8, 2008 |
| Priority date | Jan 8, 2007 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-I) receptor, e.g. a GLP-I fragment or analogue thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a subject with post-prandial hypoglycemia, comprising the step of subcutaneously administering to said subject an antagonist of the Glucagon Like Peptide-1(GLP-1) receptor, wherein said GLP-1-antagonist is a peptide, wherein the amino acid sequence of the peptide is the amino acid sequence set forth in SEQ ID NO: 1, and wherein said post-prandial hypoglycemia is associated with a gastric surgery. 2. The method of claim 1 , wherein said post-prandial hypoglycemia is associated with a Nissen fundoplication. 3. The method of claim 1 , wherein said post-prandial hypoglycemia is associated with a gastric-bypass surgery. 4. The method of claim 1 , wherein the subject is a pediatric subject. 5. The method of claim 1 , wherein the antagonist is administered at a dosage from 20 nmol/kg/day to 2000 nmol/kg/day. 6. The method of claim 1 , wherein the antagonist is administered at a dosage from 20 nmol/kg/day to 300 nmol/kg/day. 7. The method of claim 1 , wherein the antagonist is administered at a dosage of 100 nmol/kg/day. 8. The method of claim 1 , wherein the antagonist is administered at a dosage of 200 nmol/kg/day. 9. The method of claim 1 , wherein the antagonist is administered at a dosage of 300 nmol/kg/day.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9821031B2 cover?
- This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-I) receptor, e.g. a GLP-I fragment or analogue thereof.
- Who is the assignee on this patent?
- Stoffers Doris, De Leon Diva D, Stanley Charles, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/26. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).